AstraZeneca Bladder Cancer Treatment Reduced Recurrence Risk 49%
Perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced recurrence risk by 49% and risk of death by 42% in muscle-invasive bladder cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
AstraZeneca’s IMFINZI Combination Cuts Bladder Cancer Recurrence Risk 49%
Positive Phase III VOLGA trial results showed perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced recurrence risk by 49% and risk of death by 42%.